Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hasten Closes $322 Million Deal to Distribute Five Takeda Drugs in China

publication date: Mar 31, 2022

Hasten Biopharmaceutic of Hefei City has closed a deal to acquire China distribution rights to five approved prescription diabetes and cardiovascular drugs from Japan’s Takeda Pharma. Hasten is funded by CBC Group, along with Hefei Industry Investment Group and Feidong County of Hefei City. The deal was originally announced last December with a value of $322 million. At the time, CBC was not listed as an investor. Now, CBC says Hasten is part of its global healthcare ecosystem, which aims to provide better care for patients with chronic diseases. Hasten is CBC’s first drug distribution company. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital